Empagliflozin for the preservation of beta‐cell function in women with recent gestational diabetes: A randomized placebo‐controlled trial
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70146 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Shamini Murugavel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes, Gestational, Glucosides, Benzhydryl Compounds, Insulin-Secreting Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Institutes of Health Research (CIHR).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Women with a history of gestational diabetes (GDM) frequently have progressive beta‐cell dysfunction, which may result in type 2 diabetes. However, there is a paucity of clinical studies on strategies aiming to preserve beta‐cell function in this patient population. This trial evaluated whether empagliflozin can preserve beta‐cell function and reduce the prevalence of dysglycemia (prediabetes/diabetes) in women with recent GDM. Materials and Methods We conducted a double‐blind, randomized, placebo‐controlled trial where 91 women with recent GDM (6–36 months postpartum) were randomized 1:1 to either empagliflozin 10 mg/day or placebo for 48 weeks. Beta‐cell function was assessed by Insulin Secretion‐Sensitivity Index‐2 (ISSI‐2) obtained on an oral glucose tolerance test.
Results
The primary outcome of baseline‐adjusted ISSI‐2 at 48 weeks was not different between the empagliflozin and placebo group (525 ± 30.4 vs. 560 ± 33.4, p = 0.43). Additional measures of beta‐cell function, insulinogenic index/HOMA‐IR, and ΔCpep 0‐120 /Δgluc 0‐120 × Matsuda index also did not differ between the groups. While there was no difference in the secondary outcome of prevalence of dysglycemia at 48 weeks between the arms (empagliflozin 65.7% vs. 48.2% in placebo, p = 0.18), the glucose tolerance worsened in 9.4% of participants in the empagliflozin group as compared to 28% in the placebo group ( p = 0.08).
Conclusions
Empagliflozin had no significant effect on beta‐cell function in women with recent GDM. Given the sample size evaluated in this trial, the use of SGLT‐2 inhibitors warrants further study to elucidate their potential impact on T2DM prevention in women with previous GDM.
Trial registration
Clinicaltrials.gov NCT03215069
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada.
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
- Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Bernard Zinman, Caroline K Kramer
Förderung
- Canadian Institutes of Health Research (CIHR)
Zitieren
APA
Murugavel, S., Retnakaran, R., Feig, D. S., Zinman, B., & Kramer, C. K. (2025). Empagliflozin for the preservation of beta‐cell function in women with recent gestational diabetes: A randomized placebo‐controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70146
Vancouver
Murugavel S, Retnakaran R, Feig DS, Zinman B, Kramer CK. Empagliflozin for the preservation of beta‐cell function in women with recent gestational diabetes: A randomized placebo‐controlled trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70146
BibTeX
@article{Murugavel2025,
author = {Murugavel, Shamini and Retnakaran, Ravi and Feig, Denice S and Zinman, Bernard and Kramer, Caroline K},
title = {Empagliflozin for the preservation of beta‐cell function in women with recent gestational diabetes: A randomized placebo‐controlled trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70146}
}
EUVIMED